Article
Hematology
Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O'Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating
Summary: Chemoimmunotherapy with FCR achieves durable remissions, especially in patients with mutated immunoglobulin heavy chain variable gene (IGHV-M). The median progression-free survival (PFS) for IGHV-M patients is 14.6 years, compared to 4.2 years for patients with unmutated IGHV (IGHV-UM). A risk-benefit assessment is necessary when counseling patients.
Review
Oncology
Andrew H. Lipsky, Nicole Lamanna
Summary: Targeted therapies have revolutionized the frontline treatment for CLL, reducing reliance on chemoimmunotherapy. Drugs such as ibrutinib, acalabrutinib, and venetoclax have shown efficacy in oral therapy. This review explores novel therapeutic strategies using these agents in combination, highlighting the importance of patient characteristics and study methodology.
Article
Energy & Fuels
Eva Meschede, Uli Schlachter, Theys Diekmann, Benedikt Hanke, Karsten von Maydell
Summary: The aim of this analysis is to identify promising use cases for hybrid concepts of sector-coupling technologies and battery energy storage systems for frequency containment reserve (FCR). The analysis reveals that combining BESS with existing sector-coupling technology to provide FCR by lowering the power amount always generates added value.
JOURNAL OF ENERGY STORAGE
(2022)
Article
Hematology
Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg, Sunita Dwivedy Nasta, Sarah J. Nagle, Stefan K. Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S. Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P. Plastaras, Amit Maity, Agata M. Bogusz, Stacy S. Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J. Schuster
Summary: In the trial of using BV-R-CHP combination therapy for CD30-positive B-cell lymphomas, toxicity was limited with no treatment-related deaths, high overall response rate and complete response rate, high utilization of consolidative radiation, and ideal 2-year survival rates.
Article
Oncology
Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz
Summary: Abemaciclib in combination with endocrine therapy showed manageable safety and promising antitumor activity in patients with metastatic breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Summary: The study showed that adding stereotactic body radiotherapy (SBRT) to non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) therapy in metastatic renal cell carcinoma patients significantly prolonged overall survival (OS). The addition of SBRT improved OS in patients with clear-cell histology and a longer duration of response to first-line antiangiogenic therapy, with similar rates of grade >= 3 toxicities between the two treatment groups.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Lucia Carril-Ajuria, Emeline Colomba, Carmen Romero-Ferreiro, Luigi Cerbone, Raffaele Ratta, Philippe Barthelemy, Clarisse Vindry, Aude Flechon, Francois Cherifi, Elouen Boughalem, Claude Linassier, Giuseppe Fornarini, Sara E. Rebuzzi, Marine Gross-Goupil, Carolina Saldana, Maricruz Martin-Soberon, Guillermo de Velasco, Ray Manneh, Cristina Pernaut, Ana Sanchez de Torre, Ronan Flippot, Bernard Escudier, Laurence Albiges
Summary: This retrospective study analyzed the activity and safety of immune checkpoint inhibitor-based combination therapy in metastatic clear cell renal cell carcinoma patients with poor performance status (>2) in the frontline setting. The survival outcomes in this group were inferior to pivotal trials, but no significant differences were observed between nivolumab-ipilimumab (NI) and pembrolizumab-axitinib (AP). Prospective real-world studies are needed to confirm these results.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Chiun Hsu, Yi-Fang Chang, Chia-Jui Yen, Yu-Wei Xu, Min Dong, You-Zhi Tong
Summary: GT90001 plus nivolumab has a manageable safety profile and promising anti-tumor activity in patients with advanced HCC. The study results show that GT90001 combined with nivolumab treatment can effectively reduce disease progression and improve patient survival.
Article
Education, Scientific Disciplines
Vincent Levy, Alain Delmer, Florence Cymbalista
Summary: The introduction of BTKi and VEN has significantly impacted CLL treatment decisions, with consideration of patient characteristics and biomarkers. BTKi may lead to cardiovascular comorbidities and drug interactions, while the risk of VEN should be monitored at treatment initiation.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
(2021)
Article
Agriculture, Dairy & Animal Science
Jian Du, Tianchao Bao, Zhongyu Wang, Jinhua Sun
Summary: The combination of garlic oil and cooked chilli oil showed strong antibacterial activity and growth-promoting effects, leading to improved performance and meat quality in pigeons. It has the potential to be a feasible non-antibiotic strategy for pigeon production.
JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION
(2022)
Review
Immunology
Na Liu, Mengfang Liu, Shengqiao Fu, Jinglei Wang, Haowen Tang, Adamu Danbala Isah, Deyu Chen, Xu Wang
Summary: This article introduces the role of Ang2 in different cancers and pathological conditions, as well as the inhibitory effect of blocking Ang2 on cancer cell growth and metastasis. The mechanisms regulating Ang2 expression, the importance of Ang2 in cancer growth, metastasis, and prognosis, and the research and challenges of combining Ang2 inhibition with chemotherapy, immunotherapy, and radiotherapy to enhance treatment efficacy are also discussed.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Jiayan Wu, Kanyi Pu
Summary: Semiconducting polymer nanoparticles (SPNs) have been widely used in tumor treatment. Through modification, SPNs can encapsulate or conjugate with various types of immune modulators. This review summarizes the recent progress of SPNs-based combination cancer immunotherapy and highlights the synergetic effect that amplifies the anti-tumor immune response.
ADVANCED MATERIALS
(2023)
Article
Oncology
Katherine C. Fuh, Michael A. Bookman, Joyce F. Liu, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Bradley J. Monk, Randy Anderson, Gail McIntyre, Reshma Rangwala, Kathleen N. Moore
Summary: AVB-500, a novel high affinity Fc-sAXL fusion protein, combined with chemotherapy showed promising clinical activity in platinum-resistant ovarian cancer (PROC) patients, with no dose limiting toxicities observed.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Eddy S. Yang, Eric Deutsch, Altan Mehmet, Jerome Fayette, Yungan Tao, Lisle Nabell, Sharon A. Spencer, Xuejing A. Wang, Elizabeth A. Spoljoric, Wei Zhang, Scott M. Hynes, Rodney L. Decker, Aimee K. Bence Lin, William N. William
Summary: This study aimed to investigate the feasibility of combining prexasertib with cisplatin-radiotherapy or cetuximab-radiotherapy in treating HNSCC, and concluded that prexasertib could be safely combined with cetuximab-radiotherapy, although a safe dose for cisplatin-radiotherapy was not established.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Valerio Guarente, Paolo Sportoletti
Summary: Phosphoinositide 3-kinase (PI3K) inhibitors have shown potential efficacy in the treatment of chronic lymphocytic leukemia (CLL), but are limited by significant adverse events. This review discusses strategies for managing these adverse events and improving the clinical use of PI3K inhibitors in CLL treatment.
Editorial Material
Hematology
Stephen J. F. Chong, Matthew S. Davids
Article
Hematology
Matthew S. Davids, Haesook T. Kim, Caitlin Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo O. Maegawa, Alexandra Savell, Michael Mazzeo, Adrienne Anderson, Alexander P. Boardman, Augustine Weber, David Avigan, Yi-Bin Chen, Sarah Nikiforow, Vincent T. Ho, Corey Cutler, Edwin P. Alyea, Pavan Bachireddy, Catherine J. Wu, Jerome Ritz, Howard Streicher, Edward D. Ball, Asad Bashey, Robert J. Soiffer, Philippe Armand
Letter
Hematology
Matthew S. Davids, Mazyar Shadman, Sameer A. Parikh, Chaitra Ujjani, Jennifer L. Crombie, Dingfeng Jiang, Cynthia Llamas, Dai Feng, Nicole Lamanna
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown
Summary: In this study, we found that the oral Bcl-2 inhibitor venetoclax could increase the sensitivity of Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) to chemoimmunotherapy and improve treatment outcomes. In a single-arm trial, the combination of venetoclax and chemotherapy resulted in a 50% complete response rate, with deeper and more durable responses compared to historical regimens. Our data suggest that further studies comparing venetoclax with chemoimmunotherapy to chemoimmunotherapy alone are warranted.
Article
Oncology
Christine E. Ryan, Matthew S. Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P. Sharman, Anthony R. Mato, Lindsey E. Roeker
Summary: In this article, the design and rationale of the MAJIC clinical trial are described. The trial aims to compare two different treatment combinations for patients with CLL or SLL who have not received previous treatment. The primary endpoint is progression-free survival, and key secondary endpoints include undetectable minimal residual disease, overall response, and overall survival.
Article
Hematology
Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids